Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): Cross sectional study

BMJ (Online)

Volumn 343, Issue 7821, 2011, Pages

  Barr, Helen L ^a   Britton, John ^a   Smyth, Alan R ^a   Fogarty, Andrew W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SEX DIFFERENCE; SOCIAL STATUS; UNITED KINGDOM; ADOLESCENT; CHILD; CYSTIC FIBROSIS; ECONOMICS; INFANT; NEWBORN; PRESCHOOL CHILD; RISK FACTOR; SEX RATIO; SOCIAL CLASS; STATISTICAL MODEL; SURVIVAL;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; ENGLAND; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; RISK FACTORS; SEX DISTRIBUTION; SOCIAL CLASS; SURVIVAL ANALYSIS; WALES; YOUNG ADULT;

EID: 84857433891     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d4662     Document Type: Article

References (62)

1. Britton JR. Effects of social class, sex, and region of residence on age at death from cystic fibrosis. BMJ 1989;298:483-7.
2. Cystic Fibrosis Trust. UK CF registry annual report, 2008. Cystic Fibrosis Trust, 2008.
3. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991;46:881-5.
4. Walters S, Britton J, Hodson ME. Hospital care for adults with cystic fibrosis: an overview and comparison between special cystic fibrosis clinics and general clinics using a patient questionnaire. Thorax 1994;49:300-6.
5. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-6.
6. Merelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J 2001;18:306-15.
7. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr 2005;147(suppl 3):S30-6.
8. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988;41:583-91.
9. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639-42.
10. Jones AM, Govan JR, Doherty CJ, Dodd ME, Isalska BJ, Stanbridge TN, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001;358:557-8.
11. Armstrong D, Bell S, Robinson M, Bye P, Rose B, Harbour C, et al. Evidence for spread of a clonal strain of Pseudomonas aeruginosa among cystic fibrosis clinics. J Clin Microbiol 2003;41:2266-7.
12. George PM, Banya W, Pareek N, Bilton D, Cullinan P, Hodson ME, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011;342:d1008.
13. Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996;21:153-8.
14. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-6.
15. Johansen HK, Nir M, Hoiby N, Koch C, Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet 1991;337:631-4.
16. Schaedel C, Monestrol I, Hjelte L, Johannesson M, Kornfält R, Lindblad A, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002;33:483-91.
17. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-14.
18. Huang NN, Schidlow DV, Szatrowski TH, Palmer J, Laraya-Cuasay LR, Yeung W, et al. Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis. Am J Med 1987;82:871-9.
19. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
20. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-9.
21. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-61.
22. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001;163:1331-7.
23. O'Connor GT, Quinton HB, Kneeland T, Kahn R, Lever T, Maddock J, et al. Median household income and mortality rate in cystic fibrosis. Pediatrics 2003;111:e333-9.
24. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
25. Dodge JA, Morison S, Lewis PA, Colest EC, Geddes D, Russell G, et al. Cystic fibrosis in the United Kingdom, 1968-1988: incidence, population and survival. Paediatr Perinat Epidemiol 1993;7:157-66.
26. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145:794-803.
27. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-91.
28. British Paediatric Association Working Party on Cystic Fibrosis. Cystic fibrosis in the United Kingdom 1977-85: an improving picture. BMJ 1988;297:1599-602.
29. World Health Organization. Manual of international statistical classification of diseases, injuries and causes of death. 7th ed.WHO, 1957.
30. World Health Organization. Manual of the international statistical classification of diseases, injuries and causes of death. 8th ed.WHO, 1965.
31. World Health Organization. Manual of the international statistical classification of diseases, injuries and causes of death. 9th ed. WHO, 1975.
32. World Health Organization. International statistical classification of diseases and related health problems. 10th revision (ICD-10).WHO, 1994.
33. OPCS. Classification of occupations . HMSO, 1966.
34. Rose D, O'Reilly, K. The ESRC review of government social classifications: final report. The Stationery Office, 1998.
35. Rose D, Prevalin DJ, eds. A researcher's guide to the national statistics socio-economic classification . Sage Publications, 2003.
36. Adler AI, Shine BS, Chamnan P, Haworth CS, Bilton D. Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care 2008;31:1789-94.
37. Selvadurai HC, Blimkie CJ, Cooper PJ, Mellis CM, Van Asperen PP. Gender differences in habitual activity in children with cystic fibrosis. Arch Dis Child 2004;89:928-33.
38. Arrington-Sanders R, Yi MS, Tsevat J, Wilmott RW, Mrus JM, Britto MT. Gender differences in health-related quality of life of adolescents with cystic fibrosis. Health Qual Life Outcomes 2006;4:5.
39. Coakley RD, Sun H, Clunes LA, Rasmussen JE, Stackhouse JR, Okada SF, et al. 17beta-Estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia. J Clin Invest 2008;118:4025-35.
40. Zeitlin PL. Cystic fibrosis and estrogens: a perfect storm. J Clin Invest 2008;118:3841-4.
41. Schechter MS, Margolis PA. Relationship between socioeconomic status and disease severity in cystic fibrosis. J Pediatr 1998;132:260-4.
42. Balmer DF, Schall JI, Stallings VA. Social disadvantage predicts growth outcomes in preadolescent children with cystic fibrosis. J Cyst Fibros 2008;7:543-50.
43. Rubin BK. Exposure of children with cystic fibrosis to environmental tobacco smoke. N Engl J Med 1990;323:782-8.
44. Nolan T, Desmond K, Herlich R, Hardy S. Knowledge of cystic fibrosis in patients and their parents. Pediatrics 1986;77:229-35.
45. Henley LD, Hill ID. Errors, gaps, and misconceptions in the disease-related knowledge of cystic fibrosis patients and their families. Pediatrics 1990;85:1008-14.
46. Walters S, Britton J, Hodson ME. Demographic and social characteristics of adults with cystic fibrosis in the United Kingdom. BMJ 1993;306:549-52.
47. Mahadeva R, Webb K, Westerbeek RC, Carroll NR, Dodd ME, Bilton D, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998;316:1771-5.
48. Phelan P, Hey E. Cystic fibrosis mortality in England and Wales and in Victoria, Australia 1976-80. Arch Dis Child 1984;59:71-3.
49. Royal College of Physicians. Cystic fibrosis in adults. Recommendations for care of patients in the UK. Summary of a report of the Royal College of Physicians. J R Coll Physicians Lond 1991;25:12-5.
50. Jackson A. Clinical guidelines for cystic fibrosis care. Summary of guidelines prepared by a working group of the Cystic Fibrosis Trust, the British Paediatric Association, and the British Thoracic Society. J R Coll Physicians Lond 1996;30:305-8.
51. Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009;155(suppl 6):S73-93.
52. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest 2004;125(suppl 1):1-39S.
53. Bell SC. Cystic fibrosis standards of care. Cystic Fibrosis Australia, 2008.
54. Walters S. National health services for patients with cystic fibrosis: the good, the bad and the ugly. J R Soc Med 2002;95(suppl 41):32-40.
55. Elborn JS, Hodson M, Bertram C. Implementation of European standards of care for cystic fibrosis - provision of care. J Cyst Fibros 2009;8:348-55.
56. Collins CE, MacDonald-Wicks L, Rowe S, O'Loughlin EV, Henry RL. Normal growth in cystic fibrosis associated with a specialised centre. Arch Dis Child 1999;81:241-6.
57. Van Koolwijk LM, van der Laag J, Hockstra JH, Gulmans VA, van der Ent CK. Treatment of children with cystic fibrosis: central, local or both? Acta Paediatr 2002;91:972-7.
58. Hill DJ, Martin AJ, Davidson GP, Smith GS. Survival of cystic fibrosis patients in South Australia. Evidence that cystic fibrosis centre care leads to better survival. Med J Aust 1985;143:230-2.
59. Lebecque P, Leonard A, De Boeck K, De Baets F, Malfroot A, Casimir G, et al. Early referral to cystic fibrosis specialist centre impacts on respiratory outcome. J Cyst Fibros 2009;8:26-30.
60. Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr 2009;155:634-9,e1-4.
61. Penketh AR, Wise A, Mearns MB, Hodson ME, Batten JC. Cystic fibrosis in adolescents and adults. Thorax 1987;42:526-32.
62. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa : a randomized controlled trial. JAMA 2003;290:1749-56.